Bio-Techne’s Expanded RNAscope Probe Portfolio: A Game Changer in Spatial Biology
Minneapolis, MN, USA – Feb. 20, 2025 – Bio-Techne Corporation (NASDAQ: TECH), a leading innovator in the life sciences industry, is thrilled to announce the expansion of its Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio. This significant development is poised to revolutionize spatial biology research, paving the way for the creation of next-generation therapeutics and diagnostics.
Advancing Spatial Precision in Research
The expansion of the RNAscope probe portfolio now includes over 70,000 unique probes, covering more than 450 species. This extensive collection offers researchers unparalleled spatial precision in their investigations. By providing industry-leading sensitivity and specificity, Bio-Techne’s RNAscope probes enable researchers to visualize and study the exact location of RNA transcripts within cells and tissues, offering invaluable insights into biological processes and disease mechanisms.
Impact on Your Research
For researchers and scientists, this expansion of the RNAscope probe portfolio represents a significant step forward in their quest for knowledge. With access to a broader range of probes, they can now explore more intricate biological processes and gain a deeper understanding of various diseases. This, in turn, can lead to the discovery of novel therapeutic targets and diagnostics, ultimately contributing to improved patient outcomes.
Global Implications
The impact of Bio-Techne’s expanded RNAscope probe portfolio extends far beyond the scientific community. This technological advancement is expected to influence various industries, including pharmaceuticals, diagnostics, and academia, by enabling more accurate and precise research. Furthermore, it could lead to the development of targeted therapies and personalized medicine, ultimately improving healthcare outcomes and reducing costs associated with non-specific treatments.
Conclusion
Bio-Techne’s expansion of its RNAscope probe portfolio marks an exciting milestone in the realm of life sciences research. With over 70,000 unique probes now available, researchers can further their understanding of biological processes and disease mechanisms with unparalleled spatial precision. The global implications of this technological advancement are significant, with potential applications in various industries and the promise of improving healthcare outcomes and reducing costs.
- Bio-Techne’s expanded RNAscope probe portfolio includes over 70,000 unique probes for more than 450 species
- Industry-leading sensitivity and specificity enable spatial precision in research
- Impact on researchers: Enables exploration of complex biological processes and discovery of novel therapeutic targets
- Global implications: Influences pharmaceuticals, diagnostics, and academia, potentially leading to targeted therapies and personalized medicine
